Module

Mantle Cell Lymphoma: State of the Art

Source: Advances in the Treatment of Lymphoproliferative Malignancies: Promising Directions in Mantle Cell Lymphoma, Follicular Lymphoma, and Waldenstrom’s Macroglobulinemia

Mantle Cell Lymphoma: State of the Art


CME Program Director: James O. Armitage, MD

Faculty:

  • Andre Goy, MD, MPH

CME CREDIT INFORMATION

Release Date: 09/28/07

Expiration Date: 09/27/08


Physicians: maximum of 1.5 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Define the diagnosis of mantle cell lymphoma
  • Discuss the use of rituximab alone and in combination for the treatment of mantle cell lymphoma
  • Review the use of radioimmunotherapy in the treatment of patients with mantle cell lymphoma
  • Explain proteasome inhibition in the setting of mantle cell lymphoma treatment

Topics covered include:

  • Introduction
  • Diagnosis of MCL
  • Treatment of MCL
  • HyperCVAD Regimens
  • Cytotoxic Agents
  • Maintenance Therapy With Rituximab
  • Radioimmunotherapy in MCL
  • Transplantation in MCL
  • Bortezomib and Other Proteasome Inhibitors
  • Flavopiridol
  • Inhibitors of the PI3K/mTOR Pathway
  • Targeting Angiogenesis in MCL
  • Future Directions in MCL
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by University of Nebraska Medical Center, Center for Continuing Education and Clinical Care Options, LLC.

Educational grant provided by: